A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

Pfizer

Status: Not yet enrolling

Conditions: Refractory Multiple Myeloma (RRMM)

Treatments: Drug: Non intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT07391761

C1071049

Details and patient eligibility

About

The purpose of this study is to evaluate:

• What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan?
• What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan?
• What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?

Full description

This study is seeking participants who:

• have relapsed or refractory multiple myeloma (RRMM),
• have received at least four prior lines of therapy (including a PI, an IMiD, and an anti-CD38 antibody),
• are 18 years or older.

Participants receive elranatamab according to the approved label in Taiwan and continue treatment until disease progression or discontinuation. The study will evaluate real-world effectiveness and describe patient characteristics and treatment patterns to better understand elranatamab use in routine care.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients age ≥ 18 years at the initiation of elranatamab
2. Patients who have received at least one dose of elranatamab in consistent with the approved label in Taiwan.
3. Evidence of a personally signed and dated informed consent document (ICD) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. The ICD waiver is acceptable for patient who was ceased before recruitment.

Exclusion criteria

Patients who participated in any prior clinical trials using elranatamab.

Trial design

30 participants in 1 patient group

Elranatamab in Patients with Relapsed and/or Refractory Multiple Myeloma

Description:

Patients with Relapsed and/or Refractory Multiple Myeloma treated with Elranatamab

Treatment:

Drug: Non intervention